Superoxide Dismutase
European Commission authorizes Qalsody for SOD1-ALS
The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat those with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene.
FDA approves Qalsody for SOD-1 ALS
The FDA has approved Qalsody, an antisense oligonucleotide, to treat individuals with ALS associated with a mutation in the superoxide dismutase 1 gene.
European Medicines Agency accepts marketing authorization of ALS treatment
Biogen announced that the European Medicines Agency has accepted the marketing authorization application for tofersen, an investigational drug for the treatment of superoxide dismutase 1 ALS.
Phase 3 trial of tofersen shows benefits in treating rare form of ALS
A phase 3 trial that evaluated the safety and efficacy of the intrathecally administered antisense oligonucleotide tofersen reduced concentrations of superoxide dismutase 1 protein in patients with ALS who had mutations in the gene.
FDA accepts new drug application, grants priority review for ALS treatment
Biogen Inc. announced that the FDA has accepted a new drug application for tofersen, an investigational drug to treat superoxide dismutase 1 ALS.
GC4419 reduces radiation-induced severe oral mucositis among patients with head and neck cancer
The superoxide dismutase mimetic GC4419 appeared to safely and significantly reduce the duration, incidence and severity of radiation-induced severe oral mucositis compared with placebo among patients with head and neck cancer, according to results of a randomized phase 2b study published in Journal of Clinical Oncology.